MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
0.5434
-0.0018
-0.33%
After Hours: 0.5350 -0.0084 -1.55% 18:31 04/12 EDT
OPEN
0.5452
PREV CLOSE
0.5452
HIGH
0.5700
LOW
0.5234
VOLUME
1.35M
TURNOVER
0
52 WEEK HIGH
1.805
52 WEEK LOW
0.2911
MARKET CAP
110.67M
P/E (TTM)
-0.3677
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SGMO last week (0401-0405)?
Weekly Report · 5d ago
Biotech Roundtable: Who will bring the next CRISPR drug to market?
Healthcare Biotech Roundtable: Who will bring the next CRISPR drug to market? CRisPR gene editing technology has been heralded as a revolutionary breakthrough in drug development. Last fall, the FDA approved the first CRISpr product for the US market. Seeking Alpha asked three analysts to weigh in on the technology and companies working in it.
Seeking Alpha · 04/02 15:36
Weekly Report: what happened at SGMO last week (0325-0329)?
Weekly Report · 04/01 09:24
Weekly Report: what happened at SGMO last week (0318-0322)?
Weekly Report · 03/25 09:25
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Sangamo Therapeutics, Inc. Shares have retraced a considerable 36% in the last month. The company's price-to-sales ratio of 0.8x is lower than the industry average. Sangamo has been growing revenue less than most other companies in the biotech industry. The low P/S ratio is typical of a company expected to perform poorly in the future.
Simply Wall St · 03/23 14:12
12 Health Care Stocks Moving In Friday's Intraday Session
IMAC Hldgs (NASDAQ:BACK) shares moved upwards by 91.5% to $2.47 during Friday's regular session. The company's Q4 earnings report came out yesterday. Virios Therapeutics shares increased by 37.98% and Ontrak shares rose by 35.03% in the same session.
Benzinga · 03/22 17:31
Sangamo Therapeutics Shares Drop 15% After $24M Offering Prices
Sangamo Therapeutics shares were down 14% to 83 cents after the company entered a securities purchase agreement with institutional investors. The stock closed 19% higher on Thursday, and is down 53% in the past 12 months. The company entered the offering of 24.8 million shares and warrants to buy up to 28.6 million shares.
Dow Jones · 03/22 14:34
Sangamo Therapeutics looks to raise $24M in a direct offering; shares fall
Sangamo Therapeutics looks to raise $24M in a direct offering. Shares in the company down 13.2% in pre-market trade. The company says it has entered into a securities purchase agreement for the sale of 24.76M shares and pre-funded warrants.
Seeking Alpha · 03/22 12:21
More
About SGMO
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.

Webull offers Sangamo Therapeutics Inc stock information, including NASDAQ: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.